Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors: What Emergency Physicians Need to Know

被引:0
|
作者
Peyrony, O. [1 ]
Mathe, S. [1 ]
Addou, S. [1 ]
Naud, N. [2 ]
Madelaine, I. [3 ]
Baroudjian, B. [4 ]
Lebbe, C. [4 ]
Fontaine, J. -P. [1 ]
机构
[1] Hop St Louis, Assistance Publ Hop Paris AP HP, Serv Urgences, 1 Ave Claude Vellefaux, F-75010 Paris, France
[2] Sorbonne Univ, F-75006 Paris, France
[3] Hop St Louis, AP HP, Serv Pharm, 1 Ave Claude Vellefaux, F-75010 Paris, France
[4] Hop St Louis, AP HP, Serv Dermatol, 1 Ave Claude Vellefaux, F-75010 Paris, France
来源
ANNALES FRANCAISES DE MEDECINE D URGENCE | 2023年 / 13卷 / 04期
关键词
Cancer; Immunotherapy; Checkpoint inhibitors; Toxicity; PNEUMONITIS; TOXICITIES; NIVOLUMAB; BLOCKADE; MELANOMA; DIAGNOSIS; SURVIVAL;
D O I
10.3166/afmu-2022-0525
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Checkpoint inhibitors have revolutionized cancer treatments and dramatically improved the patients' prognosis. Unlike conventional cytotoxic chemotherapies, these treatments enhance immunity by restoring the anti-tumor activity of T lymphocytes and can generate immune-related adverse events. These adverse events can affect all organs, with varying degrees of severity, and sometimes, be life-threatening. The onset time can vary greatly but usually occurs in the first few months following the start of immunotherapy. These treatments and their toxicities are not well known to emergency physicians. However, the increasing use of these molecules, in extended broad indications, exposes more and more patients to these toxicities and places emergency physicians on the front line when they occur. The challenge for emergency physicians is to recognize this family of molecules and to consider possible toxicity in the presence of compatible symptoms, not to trivialize certain non-specific symptoms by too easily attributing them to cancer progression, and to consider differential diagnoses, especially infection. Since the diagnosis of toxicity can sometimes be long and complex, close collaboration with oncologists and/or organ specialists is crucial and necessary before starting treatment, which most often relies on corticosteroids and, sometimes, on immunosuppressors. We detail here the immune-related adverse events related to checkpoint inhibitors that are most common and/or severe (gastrointestinal, endocrine, cardiac, pulmonary, neuromuscular, and hepatic), with a pragmatic approach intended for emergency physicians.
引用
收藏
页码:241 / 253
页数:13
相关论文
共 50 条
  • [41] Immune-related Adverse Events in Patients With Cancer Receiving Influenza Vaccination and Immune Checkpoint Inhibitors
    Groeneveld, Geert H.
    Wijn, Dirk H.
    Vollaard, Albert M.
    CLINICAL INFECTIOUS DISEASES, 2020, 70 (07) : 1519 - 1519
  • [42] CARDIAC IMMUNE-RELATED ADVERSE EVENTS IN LUNG CANCER PATIENTS RECEIVING IMMUNE CHECKPOINT INHIBITORS
    Kumar, Sany
    Fowler, Cosmo
    Thota, Ajit K.
    Pastores, Stephen M.
    CHEST, 2023, 164 (04) : 363A - 363A
  • [43] Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer
    Simonaggio, Audrey
    Michot, Jean Marie
    Voisin, Anne Laure
    Le Pavec, Jerome
    Collins, Michael
    Lallart, Audrey
    Cengizalp, Geoffray
    Vozy, Aurore
    Laparra, Ariane
    Varga, Andrea
    Hollebecque, Antoine
    Champiat, Stephane
    Marabelle, Aurelien
    Massard, Christophe
    Lambotte, Olivier
    JAMA ONCOLOGY, 2019, 5 (09) : 1310 - 1317
  • [44] Incidence of immune-related adverse events in US veterans treated with immune checkpoint inhibitors
    Krall, Courtney
    Tague, Marshall
    Lund, Brian C.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2024, 30 (08) : 1372 - 1377
  • [45] Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors
    Cook, Sarah
    Samuel, Vanessa
    Meyers, Daniel E.
    Stukalin, Igor
    Litt, Ishjot
    Sangha, Randeep
    Morris, Don G.
    Heng, Daniel Y. C.
    Pabani, Aliyah
    Dean, Michelle
    Navani, Vishal
    JAMA NETWORK OPEN, 2024, 7 (01) : E2352302
  • [46] Histopathological predictors of immune-related adverse events among patients with melanoma treated with immune checkpoint inhibitors
    Pan, Catherina X.
    Liu, Mofei
    Lau, Charles B.
    Lau, William C.
    Kim, Daniel Y.
    Saberi, Shahin A.
    Rowley, Rachael
    Kanwar, Ruhi
    Giobbie-Hurder, Anita
    Leboeuf, Nicole R.
    Nambudiri, Vinod E.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2024, 90 (04) : 826 - 829
  • [47] Predictors of immune-related adverse events and outcomes in patients with NSCLC treated with immune-checkpoint inhibitors
    Serino, M.
    Freitas, C.
    Martins, M.
    Ferreira, P.
    Cardoso, C.
    Veiga, F.
    Santos, V.
    Araujo, D.
    Novais-Bastos, H.
    Magalhaes, A.
    Queiroga, H.
    Fernandes, G.
    Hespanhol, V.
    PULMONOLOGY, 2024, 30 (04): : 352 - 361
  • [48] Exploration of Germline Correlates and Risk of Immune-Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors
    Titmuss, Emma
    Yu, Irene S.
    Pleasance, Erin D.
    Williamson, Laura M.
    Mungall, Karen
    Mungall, Andrew J.
    Renouf, Daniel J.
    Moore, Richard
    Jones, Steven J. M.
    Marra, Marco A.
    Laskin, Janessa J.
    Savage, Kerry J.
    CURRENT ONCOLOGY, 2024, 31 (04) : 1865 - 1875
  • [49] COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
    Chen, Yu-Wei
    Tucker, Matthew D.
    Beckermann, Kathryn E.
    Iams, Wade T.
    Rini, Brian I.
    Johnson, Douglas B.
    EUROPEAN JOURNAL OF CANCER, 2021, 155 : 291 - 293
  • [50] Endocrine immune-related adverse events in patients with metastatic renal and urothelial cancer treated with immune checkpoint-inhibitors
    Immanuel Augustin Oppolzer
    Josef Riester
    Roland Büttner
    Maximilian Burger
    Marco Julius Schnabel
    International Urology and Nephrology, 2023, 55 : 1943 - 1949